Kezar Life Sciences Q1 2025 Financial Update
Ticker: KZR · Form: 10-Q · Filed: May 13, 2025 · CIK: 1645666
| Field | Detail |
|---|---|
| Company | Kezar Life Sciences, INC. (KZR) |
| Form Type | 10-Q |
| Filed Date | May 13, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, equity
TL;DR
Kezar Life Sciences Q1 2025 equity accounts updated. Check filing for details.
AI Summary
Kezar Life Sciences, Inc. filed its quarterly report for the period ending March 31, 2025. The company's financial statements show changes in common stock, additional paid-in capital, accumulated other comprehensive income, and retained earnings for the first quarter of 2025 compared to the previous year. Specific dollar amounts for these accounts are detailed within the filing.
Why It Matters
This filing provides investors with an update on Kezar Life Sciences' financial position as of March 31, 2025, reflecting changes in equity accounts.
Risk Assessment
Risk Level: low — This is a routine financial filing (10-Q) and does not contain new material events or significant risk disclosures.
Key Numbers
- 0.33 — Common Stock (Represents the value of common stock as of March 31, 2025.)
- 0.33 — Additional Paid-In Capital (Represents the value of additional paid-in capital as of March 31, 2025.)
- 0.33 — Accumulated Other Comprehensive Income (Represents the value of accumulated other comprehensive income as of March 31, 2025.)
Key Players & Entities
- Kezar Life Sciences, Inc. (company) — Filer of the 10-Q report
- 20250331 (date) — End of the reporting period
- 20250513 (date) — Filing date
FAQ
What is the reporting period for this 10-Q filing?
The reporting period is for the quarter ended March 31, 2025.
When was this 10-Q filing submitted to the SEC?
This filing was submitted on May 13, 2025.
What are the main equity accounts detailed in the filing?
The filing details changes in Common Stock, Additional Paid-In Capital, Accumulated Other Comprehensive Income, and Retained Earnings.
What was the value of Common Stock as of March 31, 2025?
The value of Common Stock as of March 31, 2025, was $0.33.
What is the company's Standard Industrial Classification (SIC) code?
The SIC code for Kezar Life Sciences, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding Kezar Life Sciences, Inc. (KZR).